Literature DB >> 27888401

The impact of chronic hepatitis C infection on cholesterol metabolism in PBMCs is associated with microRNA-146a expression.

M Sidorkiewicz1, M Grek2, B Jozwiak2, A Krol2, A Piekarska3.   

Abstract

Chronic hepatitis C (CHC) infection is known to induce important changes in host cholesterol metabolism. MicroRNAs (miRNAs) regulate the expression of many genes and, in consequence, control various processes, including human metabolism and response to viral infection. Recently, the alteration of the immune-associated miR-146a, which is abundantly present in peripheral blood mononuclear cells (PBMCs), was found in some viral infections. The study aimed to analyse the influence of hepatitis C virus (HCV) infection on miR-146a expression in PBMCs in vivo and in vitro, as well as to assess the possible impact of miR-146a alteration on the intracellular cholesterol level in PBMCs. Blood samples collected from 42 healthy donors and 72 CHC patients were the source of materials. HCV RNA, intracellular cholesterol level and miR-146a expression were determined in PBMCs, as well as HCV genotype and interferon (IFN)α concentration in sera. The influence of miR-146a inhibition on cholesterol expression in PBMCs was analysed in vitro after transient cell transfections with mirVana™ anti-miR-146a Inhibitor. Our data demonstrated an alteration of miR-146a and intracellular cholesterol expression in PBMCs and of IFNα concentration in sera of genotype 1, HCV-infected patients compared to the healthy donors. Also, in cultured PBMCs, miR-146a expression and intracellular cholesterol level were significantly decreased in CHC patients compared to the healthy donors. In vitro blockage of miR-146a expression in PBMCs of CHC patients greatly impaired intracellular cholesterol expression. In these conditions, miR-146a expression was positively correlated with the intracellular cholesterol level. These results suggest that genotype 1 HCV infection may alter miR-146a expression in PBMCs and, consequently, contribute to the observed dysregulation of cholesterol synthesis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27888401     DOI: 10.1007/s10096-016-2851-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  38 in total

1.  Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells.

Authors:  Martyna Grek; Anna Piekarska; Jacek Bartkowiak; Wojciech Fendler; Jan Kuydowicz; Piotr Wroblewski; Marek Paradowski; Malgorzata Sidorkiewicz
Journal:  Int J Mol Med       Date:  2011-07-12       Impact factor: 4.101

2.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

3.  Expression of microRNA-155 precursor in peripheral blood mononuclear cells from Hepatitis C patients after antiviral treatment.

Authors:  M Sidorkiewicz; M Grek; B Jozwiak; E Majda-Stanislawska; A Piekarska; J Bartkowiak
Journal:  Acta Virol       Date:  2010       Impact factor: 1.162

Review 4.  Innate and adaptive immune responses in HCV infections.

Authors:  Markus H Heim; Robert Thimme
Journal:  J Hepatol       Date:  2014-11-03       Impact factor: 25.083

5.  MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4.

Authors:  Ke Yang; Yu Song He; Xiao Qun Wang; Lin Lu; Qiu Jing Chen; Jing Liu; Zhen Sun; Wei Feng Shen
Journal:  FEBS Lett       Date:  2011-02-15       Impact factor: 4.124

6.  Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes.

Authors:  M Balasubramanyam; S Aravind; K Gokulakrishnan; P Prabu; C Sathishkumar; H Ranjani; V Mohan
Journal:  Mol Cell Biochem       Date:  2011-01-20       Impact factor: 3.396

Review 7.  Activation of Type I and Type III Interferons in Chronic Hepatitis C.

Authors:  Sabine Mihm
Journal:  J Innate Immun       Date:  2015-01-28       Impact factor: 7.349

Review 8.  Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies.

Authors:  Julie Blaising; Eve-Isabelle Pécheur
Journal:  Biochimie       Date:  2012-08-01       Impact factor: 4.079

9.  Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients.

Authors:  Lucy Baldeón R; Karin Weigelt; Harm de Wit; Behiye Ozcan; Adri van Oudenaren; Fernando Sempértegui; Eric Sijbrands; Laura Grosse; Wilma Freire; Hemmo A Drexhage; Pieter J M Leenen
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

Review 10.  Hepatitis C virus life cycle and lipid metabolism.

Authors:  Costin-Ioan Popescu; Laura Riva; Ovidiu Vlaicu; Rayan Farhat; Yves Rouillé; Jean Dubuisson
Journal:  Biology (Basel)       Date:  2014-12-15
View more
  4 in total

Review 1.  miRNAs regulate immune response and signaling during hepatitis C virus infection.

Authors:  Huange Zhu; Yan Geng; Qian He; Miaoxian Li
Journal:  Eur J Med Res       Date:  2018-04-18       Impact factor: 2.175

2.  The Correlation between miR-122 and Lipoprotein Lipase Expression in Chronic Hepatitis C Patients.

Authors:  Malgorzata Sidorkiewicz; Martyna Grek-Kowalinska; Anna Piekarska
Journal:  Can J Gastroenterol Hepatol       Date:  2018-07-24

3.  Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5.

Authors:  Weifeng Gong; Xiaobo Guo; Yangmin Zhang
Journal:  Yonsei Med J       Date:  2018-12       Impact factor: 2.759

Review 4.  MicroRNA Interference in Hepatic Host-Pathogen Interactions.

Authors:  Asahiro Morishita; Kyoko Oura; Tomoko Tadokoro; Koji Fujita; Joji Tani; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.